Document is current
Any future updates will be listed below
-
Authors
Remnestål, Julia
Bergström, Sofia
Olofsson, Jennie
Sjöstedt, Evelina
Uhlén, Mathias
Blennow, Kaj
Zetterberg, Henrik
Zettergren, Anna
Kern, Silke
Skoog, Ingmar
Nilsson, Peter
Månberg, Anna http://orcid.org/0000-0002-0056-1313
- License Information
-
More Information
Article History
Received: 25 November 2020
Accepted: 11 February 2021
First Online: 2 March 2021
Ethics approval and consent to participate
: The H70 study was approved by the Regional Ethical Review Board in Gothenburg (Approval Numbers: 869-13, 006-14, T703-14). The morphologically normal brain tissues obtained from the HPA project pipeline were anonymized and handled in accordance with Swedish laws and regulations (Uppsala Ethical Review Board reference # 2002-577, 2005-338 and 2007-159). The AD samples used for immunohistology staining were obtained from the Netherlands Brain Bank (ethical permission no. EPN 2013/474–31/2).
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.
